27th December 2017 - New research
Ropinirole is a dopamine agonist used for Parkinson’s Disease. It is sold as Requip, Repreve,Ronirol, and Adartrel. For more information go to : https://www.rxlist.com/requip-drug.htm
However, ropinirole undergoes extensive metabolism, resulting in a low oral bioavailability.
The necessity of frequent administration due to the short half-life of ropinirole may also
lessen patient compliance. There is consequently a pressing need to devise formulations for
the delivery of ropinirole that allow simple and easy administration. It was aimed at
overcoming all these challenges by using orally-dissolving films via sublingual delivery
(under the tongue) or buccal delivery (via tissues that line the mouth).
The ropinirole oral film was found to be non-toxic, exhibited
fast disintegration and dissolution, and was also physically
stable. Upon buccal and sublingual administration of the oral
films, ropinirole reached the systemic circulation within 15
minutes and bioavailability was significantly improved. This
may be attributable to the avoidance of first-pass metabolism
via absorption through the oral cavity.
In conclusion, the ropinirole oral film improved bioavailability after sublingual or buccal
administration. This formulation potentially overcomes biopharmaceutical challenges and
provides a convenient means of administration of ropinirole and also other Parkinson’s
Disease drugs.
Reference : Colloids and Surfaces, B Biointerfaces [2017] 163 : 9-18 [Epub ahead of print]
(K.L.Lai, Y.Fang, H.Han, Q.Li, S.Zhang, H.Y.Li, S.F.Chow, T.N.Lam, W.Y.T.Lee)
Complete abstract :
http://www.ncbi.nlm.nih.gov/pubmed/29268211
http://www.viartis.net/parkinsons.disease/news/171227
No comments:
Post a Comment